GDF11 – Comments by those not taking it
Dec 22, 2021 Rather than a “rejuvenating” agent, GDF11 may have a detrimental effect on liver senescence. Growth differentiation factor 11 accelerates liver senescence through the inhibition of autophagy [2021, open-access]
From PW of GRG: To be aware of both negatives and positives of taking GDF11.
Note: I am not currently taking it and do not plan to, even though I
could now probably afford to do so (one of the benefits of my recent
busy and stressful life).
Published: 06 October 2020
Candidate rejuvenating factor GDF11 and tissue fibrosis: friend or foe?
Jan Frohlich & Manlio Vinciguerra
GeroScience volume 42, pages1475–1498(2020)
Abstract
Growth differentiation factor 11 (GDF11 or bone morphogenetic protein
11, BMP11) belongs to the transforming growth factor-β superfamily and
is closely related to other family member—myostatin (also known as
GDF8). GDF11 was firstly identified in 2004 due to its ability to
rejuvenate the function of multiple organs in old mice. However, in the
past few years, the heralded rejuvenating effects of GDF11 have been
seriously questioned by many studies that do not support the idea that
restoring levels of GDF11 in aging improves overall organ structure and
function. Moreover, with increasing controversies, several other studies
described the involvement of GDF11 in fibrotic processes in various
organ setups. This review paper focuses on the GDF11 and its pro- or
anti-fibrotic actions in major organs and tissues, with the goal to
summarize our knowledge on its emerging role in regulating the
progression of fibrosis in different pathological conditions, and to
guide upcoming research efforts.
Full text: https://link.springer.com/article/10.1007/s11357-020-00279-w
